Now I would be surprised if we saw a US partnership materialize until after the final patient has been treated and the rATIII data from the HD phase III trial is completed. That would bring us to mid-year. In my view this means most likely it will occur close to the time when GTCB submits their BLA to the FDA. I won't speculate about Japan but that would be pretty nice to see something on that front.